Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors

PURPOSE: EC145 (vintafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with activity against FR-positive tumor xenografts in vivo. This phase I study determined the maximum-tolerated dose (MTD) of EC145 admini...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: LoRusso, Patricia M., Edelman, Martin J., Bever, Susan L., Forman, Karen M., Pilat, MaryJo, Quinn, Mary F., Li, Jing, Heath, Elisabeth I., Malburg, Lisa M., Klein, Patrick J., Leamon, Christopher P., Messmann, Richard A., Sausville, Edward A.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2012
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4104289/
https://ncbi.nlm.nih.gov/pubmed/23032618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.41.4946
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki